PURE BIOLOGICS ZY -10
Research PURE BIOLOGICS ZY -10 (PQB) on Bullrun: market cap EUR 6.22M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPQB
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 6.22M
- Financial periodQ3 2025
- Net income-EUR 1.22M
- Free cash flow-EUR 216.00K
Valuation Snapshot
latest market cap is EUR 6.22M.
About PURE BIOLOGICS ZY -10
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.
Frequently asked questions
What is PURE BIOLOGICS ZY -10's market cap?
PURE BIOLOGICS ZY -10's market capitalization is EUR 6.22M.
What does PURE BIOLOGICS ZY -10 do?
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex;